Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Delflex with Dextrose 4.25% Low Magnesium is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create a concentration gradient across the peritoneal membrane, allowing for the removal of uremic toxins and excess fluid via ultrafiltration. The low magnesium concentration (0.25 mEq/L) helps prevent hypermagnesemia in patients with renal failure.
Intraperitoneal administration of hypertonic dextrose solution creates an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of uremic toxins through peritoneal dialysis.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)
Continuous ambulatory peritoneal dialysis (CAPD) for end-stage renal diseaseContinuous cyclic peritoneal dialysis (CCPD)Off-label: Acute kidney injury requiring peritoneal dialysisOff-label: Management of severe fluid overload unresponsive to diuretics
Intraperitoneal administration: 2 L per exchange, 4 exchanges daily. Dextrose concentration (1.5%, 2.5%, or 4.25%) determined by ultrafiltration needs. Low magnesium formulation selected based on serum magnesium levels.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, or as prescribed for continuous ambulatory peritoneal dialysis (CAPD); may adjust volume and frequency based on patient's fluid and electrolyte status.
None Documented
None Documented
Intraperitoneal dextrose: absorption half-life ~1.5-2 hours; elimination of absorbed glucose follows endogenous glucose kinetics (t1/2 ~1-2 hours). Clinical note: Continuous dwell results in steady-state concentrations.
Dextrose terminal half-life is approximately 1-2 hours in normal metabolism; in peritoneal dialysis, continuous removal leads to variable half-life depending on dwell time and ultrafiltration; clinical context: continuous exposure during dwell.
Dextrose is metabolized via glycolysis and the citric acid cycle; magnesium is excreted renally and undergoes reabsorption in the kidneys; other electrolytes are regulated by renal function. No specific enzyme induction or inhibition noted.
Dextrose undergoes rapid cellular uptake and metabolism via glycolysis and subsequent oxidative phosphorylation; minimal hepatic metabolism.
Primarily renal (peritoneal clearance): ~60-80% of glucose absorbed is metabolized; dextrose metabolites (CO2, water) excreted via lungs and kidneys. Magnesium and other electrolytes are removed via peritoneal dialysis; net elimination varies with dialysis prescription.
Peritoneal dialysis solution; dextrose is metabolized and eliminated via peritoneal dialysis; approximately 70-80% of dextrose is absorbed systemically and metabolized; the non-absorbed fraction is removed with dialysate outflow; lactate (buffer) is converted to bicarbonate in the liver and eliminated via respiration and urine.
Dextrose: negligible binding. Magnesium: ~30% bound to albumin; Low Magnesium formulation minimizes magnesium load.
Dextrose: negligible (<1%); not bound to proteins.
Dextrose: Vd ~0.2-0.3 L/kg (total body water). Magnesium: Vd ~0.5-0.7 L/kg. Clinical meaning: Distributes into extracellular fluid; low Vd reflects limited tissue distribution.
Dextrose: Vd 0.2-0.4 L/kg (total body water); distributes throughout extracellular and intracellular fluid.
Intraperitoneal: dextrose absorption is 60-80% over a dwell; systemically bioavailable as absorbed glucose. Not applicable for IV or other routes.
Intraperitoneal: 100% (directly into peritoneal cavity); systemic absorption of dextrose occurs via peritoneal capillaries (70-80% absorbed over dwell).
No dose adjustment for renal impairment; drug is administered intraperitoneally for peritoneal dialysis. Monitor serum electrolytes and ultrafiltration.
No dose adjustment required for renal impairment; however, monitor serum electrolytes and fluid balance closely in patients with residual renal function.
No specific adjustment; caution in hepatic impairment due to risk of lactate metabolism impairment with dextrose. Monitor serum lactate and electrolytes.
No specific dose adjustment recommended; use with caution in severe hepatic impairment due to risk of electrolyte disturbances and fluid overload.
Weight-based: 30-40 mL/kg per exchange, 4-5 exchanges daily. Adjust dextrose concentration based on ultrafiltration target. Low magnesium product used if hypermagnesemia risk.
Individualized based on weight, body surface area, and peritoneal dialysis prescription; typical exchange volume: 30-40 mL/kg per exchange, 4-5 exchanges per day for CAPD; adjust dextrose concentration based on ultrafiltration needs.
No specific dose adjustment; monitor fluid status, electrolytes, and ultrafiltration volume closely due to increased risk of volume overload and electrolyte disturbances.
No specific dose adjustment; monitor for fluid overload and electrolyte imbalances, adjust dextrose concentration and exchange volume as needed, consider reduced volume and frequency in patients with compromised cardiac or renal function.
None
None.
["Not for intravenous use","Risk of peritonitis","Electrolyte imbalance (hypokalemia, hypomagnesemia, hypocalcemia)","Fluid overload or dehydration","Hyperglycemia, especially in diabetic patients","Abdominal wall hernias","Ileus or mechanical obstruction","Encapsulating peritoneal sclerosis (rare)"]
["Peritonitis: Use strict aseptic technique; monitor for signs of infection","Mechanical complications: Catheter malfunction, leakage, hernia","Metabolic disturbances: Hyperglycemia, hyperosmolarity, electrolyte imbalances","Hypersensitivity: Rare allergic reactions to components","Volume overload: Monitor ultrafiltration and body weight"]
["Pre-existing severe hypokalemia","Hypercalcemia","Severe hyperglycemia uncorrected","Significant abdominal adhesions or fibrosis","Pre-existing peritoneal diaphragmatic defects","History of severe pancreatitis or diverticulitis","Inability to perform dialysis exchanges safely"]
["Pre-existing severe hyperglycemia","Hypersensitivity to dextrose or any component","Clinically significant peritoneal membrane abnormalities (e.g., extensive adhesions, recent surgery)","Severe respiratory acidosis (relative contraindication)"]
Data Pending Review
Data Pending Review
No direct food interactions with the solution itself, but dietary management is critical. Magnesium-restricted diet advised if serum magnesium is elevated; avoid high-magnesium foods like nuts, seeds, legumes, whole grains, chocolate, bananas, and dark leafy greens. Dextrose content may affect glycemic control; diabetic patients should monitor carbohydrate intake and adjust insulin as needed. Potassium and phosphorus restrictions may also apply based on individual lab values.
No direct food interactions with Delflex-LM w/ Dextrose 4.25% as it is intraperitoneal. However, dietary restrictions for renal failure apply: limit sodium, potassium, phosphorus, and fluid intake. Dextrose absorption may affect blood glucose; diabetic patients should adjust diet and insulin accordingly.
Delflex with Dextrose 4.25% Low Magnesium is a peritoneal dialysis solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this solution. In general, peritoneal dialysis may cause electrolyte disturbances and fluid shifts that could affect fetal well-being. Hyperglycemia from dextrose absorption may pose risks during organogenesis (first trimester) and later trimesters. Use only if clearly needed and monitor maternal glucose and electrolytes closely.
Insufficient human data; animal studies not available. Icodextrin and dextrose are not known teratogens, but risks cannot be excluded. In first trimester, theoretical risk of metabolic disturbance; second and third trimesters, possible volume overload. Use only if clearly needed.
It is not known whether Delflex components are excreted in human milk. Dextrose is a normal constituent of milk. Calcium, magnesium, and sodium are present in milk and the additional amounts from dialysis are likely negligible. However, due to potential for systemic absorption of dextrose and electrolyte shifts, caution is advised. No M/P ratio is available.
Unknown if icodextrin or dextrose metabolites excreted in human milk. M/P ratio not established. Caution in breastfeeding women; consider benefits vs risks.
Dosing of peritoneal dialysis solution (volume, dwell time, number of exchanges) should be individualized based on maternal renal function, electrolyte status, and glycemic control. Pregnancy may require increased dialysis dose due to increased metabolic demands and volume of distribution. Monitor blood glucose closely as dextrose absorption can cause hyperglycemia; insulin adjustment may be necessary. No specific dose adjustment of the solution is defined; clinical judgment and frequent monitoring are required.
No specific dose adjustments established; pharmacokinetic changes in pregnancy (increased plasma volume, renal function) may affect drug clearance. Monitor adequacy of dialysis and adjust exchange volume/frequency as needed to maintain target solute clearance and ultrafiltration.
Category C
Category C
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM is a peritoneal dialysis solution indicated for patients with end-stage renal disease (ESRD) to remove waste products and excess fluid via the peritoneal membrane. The low magnesium formulation (0.5 mEq/L) is specifically designed for patients at risk of hypermagnesemia, such as those with impaired renal function or on magnesium-containing medications. Monitor serum magnesium levels regularly; hypomagnesemia is also possible if dietary intake is insufficient. The 4.25% dextrose concentration provides the highest ultrafiltration capacity among standard solutions, making it suitable for fluid overload states. Use with caution in patients with severe hyperglycemia or glucose intolerance, as the dextrose load may elevate blood glucose. Ensure sterile technique during bag exchange to prevent peritonitis.
Delflex-LM w/ Dextrose 4.25% is a peritoneal dialysis solution. Verify solution clarity and integrity before use. Warm solution to body temperature to minimize discomfort. Use aseptic technique for all connections to reduce peritonitis risk. Monitor effluent for clarity; cloudy effluent may indicate infection. Check blood glucose levels closely in diabetic patients due to dextrose absorption. Adequacy of dialysis should be assessed by Kt/V and creatinine clearance. Do not administer intravenously.
Wash hands thoroughly before handling the dialysis bag or catheter site.Inspect the solution bag for cloudiness, discoloration, or leaks; do not use if present.Use only as directed by your healthcare provider about the number and duration of exchanges.Report any signs of infection such as redness, swelling, or drainage at the catheter site, or abdominal pain, fever, or nausea.Monitor your blood glucose levels if you have diabetes, as the dextrose in the solution may raise blood sugar.Follow a kidney-friendly diet as recommended, which may include limiting certain foods high in magnesium (e.g., nuts, seeds, leafy greens) if your magnesium levels are high.Do not reuse the dialysis bag or tubing; dispose as instructed.Keep a log of your daily weight and report any rapid weight gain or persistent edema.Avoid vigorous exercise that could dislodge the catheter.Seek immediate medical attention if you experience shortness of breath, chest pain, or severe abdominal pain.
Store solution at room temperature, avoid extreme heat or cold.Check solution bag for leaks, cloudiness, or discoloration before use; do not use if compromised.Warm the solution to body temperature (use dry heat, not microwave) before infusion.Perform exchange in a clean, well-lit area and wash hands thoroughly.Use sterile technique when connecting and disconnecting lines.Monitor your weight and blood pressure daily and report changes.Report any signs of peritonitis: cloudy effluent, abdominal pain, fever, nausea, or vomiting.Follow a renal diet as advised by your dietitian, including fluid, sodium, potassium, and phosphorus restrictions.Do not reuse solution or administration sets.Contact healthcare provider if you experience shortness of breath or swelling (signs of fluid overload).